Umecrine Cognition AB Feed

2026-10-21 16:00:00 Umecrine Cognition receives Notice of Allowance from the USPTO for treatment of primary biliary cholangitis symptoms with golexanolone

2026-10-20 09:00:00 Umecrine Cognition patient survey on Impact of Fatigue in PBC selected as a Poster of Distinction for The Liver Meeting 2026

2026-10-07 12:59:00 Umecrine Cognition invited to showcase Parkinson’s disease program and new translational data at The Michael J. Fox Foundation’s 18th Annual PDTC 2026

2026-09-15 08:45:00 Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis

2026-09-07 08:59:00 Umecrine Cognition receives Notice of Allowance in the US for patents protecting second-generation GAMSA compounds

2026-08-03 13:00:00 Umecrine Cognition enrolls last patient in its ongoing Phase 1b/2a study of golexanolone

2026-06-23 14:15:00 Umecrine Cognition completes interim sample size analysis in Phase 1b/2a study of golexanolone

2026-06-08 08:30:00 Umecrine Cognition resolves directed share issue of SEK 64 million to complete its clinical Phase 1b/2a study

2026-05-27 08:45:00 Umecrine Cognition presents PBC patient survey data at EASL 2026 revealing central fatigue as the most burdensome symptom

2026-05-13 08:45:00 Umecrine Cognition will present patient survey data at EASL 2026 suggesting golexanolone addresses critical unmet need in PBC

2025-11-19 08:45:00 Umecrine Cognition publishes review highlighting the therapeutic potential of golexanolone in treating neuroinflammatory disorders

2025-11-17 08:45:00 Umecrine Cognition reports early golexanolone treatment yields sustained benefit in a preclinical model of Parkinson’s disease

2025-10-09 10:20:00 Notice to attend the Extraordinary General Meeting in Umecrine Cognition AB, at 2:30 p.m.

2025-09-25 11:00:00 Notice to attend the Extraordinary General Meeting in Umecrine Cognition AB

2025-09-04 08:45:00 Umecrine Cognition publishes data showing sustained reversal of neuroinflammation in Parkinson’s disease model

2025-07-14 11:00:00 Umecrine Cognition raises SEK 24,6 million for the ongoing clinical Phase 1b/2a study of golexanolone

2025-05-26 08:45:00 Umecrine Cognition resumes patient inclusion in its clinical Phase I/IIa study of golexanolone in primary biliary cholangitis

2025-05-20 08:45:00 Notice to attend the Annual General Meeting in Umecrine Cognition AB

2025-05-07 08:45:00 Umecrine Cognition to present a novel clinically validated symptom severity scale in Primary Biliary Cholangitis at EASL 2025

2025-05-05 08:45:00 Umecrine Cognition receives a grant from The Michael J. Fox Foundation to support preclinical evaluation of golexanolone in Parkinson’s disease

2025-04-07 08:45:00 Umecrine Cognition attends the International PBC Summit 2025

2025-04-01 13:00:00 Umecrine Cognition appoints Viktor Drvota as new CEO

2025-04-01 08:45:00 Umecrine Cognition presents nonclinical data at AD/PD™ 2025 showing that golexanolone reverses dopamine loss and sustains improvements of Parkinsonian symptoms

2025-03-18 14:45:00 Umecrine Cognition provides update on the Phase 1b/2a clinical study of golexanolone

2025-03-17 08:45:00 Umecrine Cognition will attend BIO-Europe Spring® 2025 in Milan

2025-01-13 08:45:00 Umecrine Cognition attends the 43rd Annual JP Morgan Healthcare Conference

2024-12-19 08:45:00 Umecrine Cognition raises MSEK 23,8 to the ongoing clinical Phase 1b/2 study of golexanolone

2024-11-18 08:45:00 Umecrine Cognition presents positive interim data from ongoing Phase 1b/2a study with golexanolone at the AASLD Liver Meeting in San Diego

2024-10-17 08:45:00 Umecrine Cognition attends INBC 2024 to present new preclinical data showing conserved dopamine signaling in Parkinson’s disease

2024-07-10 08:45:00 Umecrine Cognition raises MSEK 28.3 for the ongoing clinical development of golexanolone

2024-06-28 08:45:00 Umecrine Cognition publishes new nonclinical data for golexanolone in Parkinson’s disease that will be presented at the FENS Forum 2024

2024-06-03 08:45:00 Umecrine Cognition attends BIO 2024 in San Diego

2024-05-08 08:45:00 Umecrine Cognition’s Phase 2 study of golexanolone in Primary Biliary Cholangitis has randomized its first two patients

2024-04-16 08:45:00 Umecrine Cognition publishes scientific review on the role of endogenous neurosteroids in neuroinflammation and their potential therapeutic effect

2024-03-22 08:45:00 Umecrine Cognition’s Phase 1b/2 study of golexanolone in Primary Biliary Cholangitis progresses to Part B following positive safety review

2024-03-18 08:45:00 Umecrine Cognition will attend BIO-Europe Spring® 2024 in Barcelona

2024-03-15 09:00:00 Scientific review of golaxonolone’s therapeutic potential on symptoms arising from neuroinflammation published in Frontiers in Pharmacology

2024-03-06 08:45:00 Umecrine Cognition presents nonclinical data at AD/PD™ 2024 further elucidating golexanolone’s mode-of-action in Parkinson’s disease

2024-01-08 08:45:00 Umecrine Cognition attends the JP Morgan 42nd Annual Healthcare Conference 2024 in San Francisco

2023-11-28 10:30:00 Umecrine Cognition presents preclinical results showing significant decreases in PBC-like symptomology and neuroinflammation

2023-11-17 08:45:00 Umecrine Cognition raises further funding for the clinical development of golexanolone

2023-07-05 08:45:00 Umecrine Cognition presents data at World Parkinson Congress showing positive effects of golexanolone in a preclinical model of Parkinson’s disease

2023-06-07 11:50:00 Umecrine Cognition presents new preclinical data that elucidates the mechanism-of-action of golexanolone in cholestatic liver disease

2023-05-17 08:45:00 Notice to attend the Annual General Meeting in Umecrine Cognition AB

2023-04-17 08:45:00 First patient included in Umecrine Cognition’s clinical Phase 2 study of golexanolone in primary biliary cholangitis

2023-03-28 08:45:00 Umecrine Cognition secures additional funding to progress its drug development projects

2023-01-17 08:45:00 Umecrine Cognition announces Orphan Drug Designation granted by FDA for golexanolone

2023-01-09 08:45:00 Umecrine Cognition will attend the JP Morgan 41st Annual Healthcare Conference 2023 in San Francisco

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode